Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1533932

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1533932

MEK Inhibitors

PUBLISHED:
PAGES: 132 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5600
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 16800

Add to Cart

Description

Table of Contents

Global MEK Inhibitors Market to Reach US$1.5 Billion by 2030

The global market for MEK Inhibitors estimated at US$995.1 Million in the year 2023, is expected to reach US$1.5 Billion by 2030, growing at a CAGR of 5.9% over the analysis period 2023-2030.

The U.S. Market is Estimated at US$271.1 Million While China is Forecast to Grow at 9.6% CAGR

The MEK Inhibitors market in the U.S. is estimated at US$271.1 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$316.8 Million by the year 2030 trailing a CAGR of 9.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 6.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.

Global MEK Inhibitors Market - Key Trends and Drivers Summarized

MEK inhibitors are a class of targeted therapy drugs that inhibit the activity of the mitogen-activated protein kinase (MEK) enzyme, which plays a significant role in the MAPK/ERK signaling pathway. This pathway is crucial for cell division and differentiation, and its dysregulation is often found in various types of cancer, including melanoma, non-small cell lung cancer, and thyroid cancer. By targeting MEK, these inhibitors can help control the growth and spread of cancer cells. MEK inhibitors, such as trametinib and cobimetinib, are typically used in combination with other therapies, such as BRAF inhibitors, to enhance their efficacy. This combination has proven to be effective particularly in melanoma patients who have specific mutations in the BRAF gene, significantly improving patient outcomes in terms of progression-free survival rates and overall response to treatment.

The development of MEK inhibitors has been a part of the broader trend in oncology towards precision medicine, where treatments are increasingly tailored to the genetic profile of an individual’s tumor. This shift has led to more effective and less toxic cancer treatments. Ongoing research in the field of oncogenomics continues to identify the molecular drivers of cancer, providing a rich pipeline of potential targets for new MEK inhibitors. As our understanding of tumor biology deepens, MEK inhibitors are being tested in a wider range of cancers and in different combinations with other targeted therapies, immune checkpoint inhibitors, and traditional chemotherapies. This exploration of novel therapeutic combinations and sequences aims to overcome resistance that often develops with cancer treatments, thereby improving the durability of cancer responses and outcomes for patients.

The growth in the MEK inhibitors market is driven by several factors, including the rising prevalence of cancers that are susceptible to these treatments and the ongoing discoveries in cancer genomics that offer insights into new therapeutic targets. The expansion of clinical trials to explore different combinations and sequences of MEK inhibitors with other cancer therapies is also a critical factor, pushing the boundaries of current cancer treatment paradigms. Furthermore, advancements in diagnostic technologies that allow for quicker and more accurate identification of mutations in cancer cells facilitate the appropriate selection of patients who are likely to benefit from MEK inhibitor therapies. Consumer behavior, particularly the increasing demand for more personalized and less invasive treatment options, further fuels the adoption of targeted therapies like MEK inhibitors. Lastly, regulatory incentives for the development of orphan drugs and fast-track approval processes in many countries encourage pharmaceutical companies to invest in the research and development of these drugs, ensuring a robust pipeline of new MEK inhibitors entering the market. This combination of scientific advancement, clinical need, regulatory support, and market demand ensures continued growth and innovation within the MEK inhibitors market, promising improved outcomes for cancer patients around the world.

Select Competitors (Total 36 Featured) -

  • AstraZeneca plc
  • Boehringer Ingelheim International GmbH
  • Day One Biopharmaceuticals, Inc.
  • Genentech, Inc
  • Golden Biotechnology Corporation
  • Immuneering Corportion
  • Merck KGaA (MilliporeSigma)
  • Novartis International AG
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • Pierre Fabre S.A.
  • Shanghai Fosun Pharmaceutical (Group) Co., Ltd
  • SpringWorks Therapeutics Inc
  • Suzhou Zelgen Biopharmaceuticals Co., Ltd
  • Verastem, Inc.
  • ;
Show more
Product Code: MCP26804

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • MEK Inhibitors - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Understanding the Value of MEK Inhibitors in Cancer & Cancer Therapy
    • Increased Incidence of Melanoma and Other Cancers Propel Demand
    • Integration of MEK Inhibitors in Combination Cancer Therapy Protocols
    • Expansion of Treatment Indications Beyond Oncology
    • Market Entry of Generic and Biosimilar Therapeutic Options
    • Ethical and Regulatory Issues in Cancer Drug Trials
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World MEK Inhibitors Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for MEK Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for MEK Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for MEK Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • MEK Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 5: USA Recent Past, Current & Future Analysis for MEK Inhibitors by Segment - MEK Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 6: USA Historic Review for MEK Inhibitors by Segment - MEK Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • CANADA
    • TABLE 7: Canada Recent Past, Current & Future Analysis for MEK Inhibitors by Segment - MEK Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 8: Canada Historic Review for MEK Inhibitors by Segment - MEK Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • JAPAN
    • MEK Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 9: Japan Recent Past, Current & Future Analysis for MEK Inhibitors by Segment - MEK Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 10: Japan Historic Review for MEK Inhibitors by Segment - MEK Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • CHINA
    • MEK Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 11: China Recent Past, Current & Future Analysis for MEK Inhibitors by Segment - MEK Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 12: China Historic Review for MEK Inhibitors by Segment - MEK Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • EUROPE
    • MEK Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 13: Europe Recent Past, Current & Future Analysis for MEK Inhibitors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 14: Europe Historic Review for MEK Inhibitors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 15: Europe 16-Year Perspective for MEK Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • FRANCE
    • MEK Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 16: France Recent Past, Current & Future Analysis for MEK Inhibitors by Segment - MEK Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 17: France Historic Review for MEK Inhibitors by Segment - MEK Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • GERMANY
    • MEK Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 18: Germany Recent Past, Current & Future Analysis for MEK Inhibitors by Segment - MEK Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 19: Germany Historic Review for MEK Inhibitors by Segment - MEK Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • ITALY
    • TABLE 20: Italy Recent Past, Current & Future Analysis for MEK Inhibitors by Segment - MEK Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Italy Historic Review for MEK Inhibitors by Segment - MEK Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • UNITED KINGDOM
    • MEK Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 22: UK Recent Past, Current & Future Analysis for MEK Inhibitors by Segment - MEK Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 23: UK Historic Review for MEK Inhibitors by Segment - MEK Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • SPAIN
    • TABLE 24: Spain Recent Past, Current & Future Analysis for MEK Inhibitors by Segment - MEK Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 25: Spain Historic Review for MEK Inhibitors by Segment - MEK Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • RUSSIA
    • TABLE 26: Russia Recent Past, Current & Future Analysis for MEK Inhibitors by Segment - MEK Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Russia Historic Review for MEK Inhibitors by Segment - MEK Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • REST OF EUROPE
    • TABLE 28: Rest of Europe Recent Past, Current & Future Analysis for MEK Inhibitors by Segment - MEK Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 29: Rest of Europe Historic Review for MEK Inhibitors by Segment - MEK Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • ASIA-PACIFIC
    • MEK Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 30: Asia-Pacific Recent Past, Current & Future Analysis for MEK Inhibitors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 31: Asia-Pacific Historic Review for MEK Inhibitors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 32: Asia-Pacific 16-Year Perspective for MEK Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • AUSTRALIA
    • MEK Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 33: Australia Recent Past, Current & Future Analysis for MEK Inhibitors by Segment - MEK Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 34: Australia Historic Review for MEK Inhibitors by Segment - MEK Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • INDIA
    • MEK Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 35: India Recent Past, Current & Future Analysis for MEK Inhibitors by Segment - MEK Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: India Historic Review for MEK Inhibitors by Segment - MEK Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • SOUTH KOREA
    • TABLE 37: South Korea Recent Past, Current & Future Analysis for MEK Inhibitors by Segment - MEK Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 38: South Korea Historic Review for MEK Inhibitors by Segment - MEK Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • REST OF ASIA-PACIFIC
    • TABLE 39: Rest of Asia-Pacific Recent Past, Current & Future Analysis for MEK Inhibitors by Segment - MEK Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 40: Rest of Asia-Pacific Historic Review for MEK Inhibitors by Segment - MEK Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • LATIN AMERICA
    • MEK Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 41: Latin America Recent Past, Current & Future Analysis for MEK Inhibitors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 42: Latin America Historic Review for MEK Inhibitors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Latin America 16-Year Perspective for MEK Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 44: Argentina Recent Past, Current & Future Analysis for MEK Inhibitors by Segment - MEK Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Argentina Historic Review for MEK Inhibitors by Segment - MEK Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • BRAZIL
    • TABLE 46: Brazil Recent Past, Current & Future Analysis for MEK Inhibitors by Segment - MEK Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 47: Brazil Historic Review for MEK Inhibitors by Segment - MEK Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • MEXICO
    • TABLE 48: Mexico Recent Past, Current & Future Analysis for MEK Inhibitors by Segment - MEK Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 49: Mexico Historic Review for MEK Inhibitors by Segment - MEK Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • REST OF LATIN AMERICA
    • TABLE 50: Rest of Latin America Recent Past, Current & Future Analysis for MEK Inhibitors by Segment - MEK Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Rest of Latin America Historic Review for MEK Inhibitors by Segment - MEK Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • MIDDLE EAST
    • MEK Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 52: Middle East Recent Past, Current & Future Analysis for MEK Inhibitors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 53: Middle East Historic Review for MEK Inhibitors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 54: Middle East 16-Year Perspective for MEK Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • IRAN
    • TABLE 55: Iran Recent Past, Current & Future Analysis for MEK Inhibitors by Segment - MEK Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 56: Iran Historic Review for MEK Inhibitors by Segment - MEK Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • ISRAEL
    • TABLE 57: Israel Recent Past, Current & Future Analysis for MEK Inhibitors by Segment - MEK Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 58: Israel Historic Review for MEK Inhibitors by Segment - MEK Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • SAUDI ARABIA
    • TABLE 59: Saudi Arabia Recent Past, Current & Future Analysis for MEK Inhibitors by Segment - MEK Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Saudi Arabia Historic Review for MEK Inhibitors by Segment - MEK Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • UNITED ARAB EMIRATES
    • TABLE 61: UAE Recent Past, Current & Future Analysis for MEK Inhibitors by Segment - MEK Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 62: UAE Historic Review for MEK Inhibitors by Segment - MEK Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • REST OF MIDDLE EAST
    • TABLE 63: Rest of Middle East Recent Past, Current & Future Analysis for MEK Inhibitors by Segment - MEK Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 64: Rest of Middle East Historic Review for MEK Inhibitors by Segment - MEK Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • AFRICA
    • MEK Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 65: Africa Recent Past, Current & Future Analysis for MEK Inhibitors by Segment - MEK Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Africa Historic Review for MEK Inhibitors by Segment - MEK Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!